Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English

Successful completion of the OPPIK project ” Transfer factor – research and development of a new dosage form of immunotherapeutic medicinal product “

Prototyp TFI1

This year, company AUMED a.s. successfully completed a multi-year project of the OPPIK program entitled “Transfer factor – research and development of a new dosage form of immunotherapeutic medicinal product” (project number CZ.01.1.02/0.0/0.0/16_083/0010301).

The subject of the project was preparation of a new dosage form of specific immunomodulators based on transfer factors (TF) and methods of testing their immunobiological potential. The research and development of the final product (lyophilized tablets) was completed. The final product was transferred from the laboratory preparation mode to the production – technological arrangement. Experimental samples were made in the form of lyophilized tablets and tested for biological efficacy. The result of the prototype and pilot plant was completed.

The main benefit of the project is an innovatively enhanced medical product of specific immunomodulators based on human transfer factors (TF) administered orally as a lyophilized tablet, which solves both painful administration in the first case and influencing the efficacy of transfer factors by the digestive system when administered orally in liquid form. The composition of the medicinal product is a dialysate of peripheral blood leukocyte homogenate, a physiologically balanced mixture of biologically active substances that occur naturally in the body and perform specific functions in the immune system. Human leukocytes are a natural tool of the immune system. The main mission of this drug is to normalize cellular immunity by transferring specific cellular immunity from the donor to the recipient. New commercially-interesting medication is fully developer and ready for registration!

The medical product is designed for treatment primarily in cases of laboratory-proven cellular immune deficiency, as well as in clinical cases of diseases known to be usually associated with cellular immune deficiency. It will also be indicated in humoral immune deficiencies with laboratory evidence of decreased immunoglobulin levels, and fluctuating findings of impaired cellular immunity, with relapsing infections of various locations.

MORE ARTICLES

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”

29. 11. 2022

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As…

AUMED, a.s. presented phage research at the Phages 2022 conference in Oxford

26. 09. 2022

AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a…

AUMED a.s. founded a new company AUMED Immunology a.s.

19. 09. 2022

AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company….

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle
TFI Transfer Factor – Medicine

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s